Metabolic & Endocrine · Clinical trials
Polycystic Ovary Syndrome (PCOS) Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About polycystic ovary syndrome (pcos) — and why its trials are hard
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, defined by the Rotterdam criteria requiring two of: oligo/anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. It causes menstrual irregularity, infertility, hirsutism, acne, and is strongly linked to insulin resistance, obesity, type 2 diabetes, dyslipidemia and endometrial risk. Critically, there is no FDA-approved drug for PCOS itself; management is symptom-directed and relies entirely on off-label pharmacotherapy. Combined oral contraceptives regulate cycles and reduce androgens; metformin improves insulin sensitivity and menstrual regularity; spironolactone treats hirsutism; and for ovulation induction, letrozole (now preferred over clomiphene) improves live-birth rates. Lifestyle modification remains foundational. The absence of any agent developed and approved specifically for the syndrome, combined with its heterogeneity and metabolic burden, represents a major unmet need. Emerging interest centers on GLP-1 receptor agonists for weight and metabolic benefit and on novel neuroendocrine targets, but none carries a PCOS-specific regulatory indication, leaving practice dependent on repurposed drugs.
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in polycystic ovary syndrome (pcos) development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Troglitazone (thiazolidinedione insulin sensitizer) — PCOS ovulation/insulin-sensitivity studies (late 1990s) | Improved ovulation and hyperandrogenism in PCOS but the drug was withdrawn from the market in 2000; never pursued to a PCOS-specific approval | Severe idiosyncratic hepatotoxicity leading to worldwide market withdrawal |
| Flutamide (non-steroidal antiandrogen) — Off-label hirsutism/hyperandrogenism studies | Reduced hirsutism but never gained a PCOS indication and use is discouraged | Dose-dependent hepatotoxicity risk outweighing benefit versus safer alternatives (magnitude unverified) |
Choosing the right endpoint
Primary endpoints that matter in polycystic ovary syndrome (pcos) trials
- Ovulation / menstrual regularity — Restoration of ovulatory cycles; central to fertility-focused management
- Live birth rate — Definitive fertility endpoint (letrozole superior to clomiphene in ovulation-induction trials)
- Hyperandrogenism (hirsutism, testosterone) — Modified Ferriman-Gallwey score and androgen levels track dermatologic response
- Insulin resistance / glycemic measures — HOMA-IR, HbA1c and weight capture the metabolic dimension addressed by metformin/lifestyle
- Metabolic and weight outcomes — Weight, lipids and glucose reflect long-term cardiometabolic risk reduction
How iNGENū runs polycystic ovary syndrome (pcos) trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Polycystic Ovary Syndrome (PCOS) clinical trials — FAQs
Is there an FDA-approved medication for PCOS?
Why is metformin used if it is not approved for PCOS?
What is first-line for fertility in PCOS?
Ready to discuss your polycystic ovary syndrome (pcos) trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal